Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling

Medicine and Dentistry

• Glioblastoma 100%
• Guanabenz 100%
• Sunitinib 100%
• Autophagy 50%
• Temozolomide 16%
• Cytotoxicity 16%
• In Vitro 8%
• Programmed Cell Death 8%
• Protein Tyrosine Kinase 8%
• Combined Therapy 8%
• Mitogen Activated Protein Kinase P38 8%
• Combination Therapy 8%
• RNA Sequence 8%
• Sympathomimetic Drug 8%
• Treatment Effect 8%
• Oncogene 8%
• Colony Formation 8%
• Ganglioglioma 8%
• Kinase Signaling 8%
• Xenograft 8%
• Tyrosine-Kinase Inhibitor 8%
• DNA Damage 8%
• Drug Sensitivity 8%
• Growth Disorder 8%
• In Silico 8%
• Hypoxic Cell 8%
• Cell Culture 8%
• Transcriptome 8%
• Adjuvant 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Glioblastoma 100%
• Guanabenz 100%
• Sunitinib 100%
• Cytotoxicity 16%
• Temozolomide 16%
• Mouse 8%
• RNA-Sequencing 8%
• Mitogen Activated Protein Kinase P38 8%
• Adrenergic Receptor Stimulating Agent 8%
• Protein Tyrosine Kinase Inhibitor 8%
• Protein Tyrosine Kinase 8%
• Combination Therapy 8%
• Transcriptome 8%
• Adjuvant 8%
• Growth Disorder 8%